Glenmark Launches Olanzapine for Injection in USA, Enhancing Injectables Portfolio
Glenmark Pharmaceuticals Inc., USA has announced the launch of Olanzapine for Injection, 10 mg/vial, Single-Dose Vial. This introduction expands Glenmark's offerings within the mental health sector, positioning the drug as a bioequivalent and therapeutically equivalent alternative to the reference listed medication, Zyprexa® IntraMuscular Injection 10 mg/vial, which is associated with Cheplapharm Registration GmbH [NDA 021253].The launch comes against a market context where IQVIA data for the 12-month period ending May 2026 showed that the Zyprexa® IntraMuscular Injection market achieved annual sales of approximately $25.4 million*. Market analysis used by Glenmark includes both brand and all available therapeutic equivalents.
Commenting on the strategic move, Marc Kikuchi, President & Business Head for North America at Glenmark, stated that the launch underscores a focused effort to grow a robust injectables portfolio. He added that the product strengthens the company's presence within the institutional channel and reflects a commitment to expanding access to quality and affordable treatment options for patients and healthcare providers.
Glenmark Pharmaceuticals Limited is recognized as a global, research-led pharmaceutical organization specializing in innovation and accessibility. The company pioneers breakthrough therapies with a focus on respiratory, dermatology, and oncology products. Glenmark operates through 11 world-class manufacturing facilities spread across four continents, supported by six R&D centers, and maintains a commercial footprint in over 80 countries. Furthermore, the company was ranked among the Top 100 biopharmaceutical companies globally by pharmaceutical sales for 2024.
*IQVIA® National Sales Perspectives: Retail & Non-Retail, May 2026.
GLENMARK Stock Price Movement
On Friday, shares of Glenmark Pharmaceuticals Limited edged higher in the market, closing at ₹2211 after gaining 0.87%. The stock traded with a volume of 632,010 shares and saw a daily trading range between ₹2185.2 and ₹2244.5.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.